...
search icon
ino-img

Inovio Pharmaceuticals Inc, Common Stock

INO

NAQ

$1.85

+$0.07

(3.93%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$64.55M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
504.83K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
1.84
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$1.42 L
$13.44 H
$1.85

About Inovio Pharmaceuticals Inc, Common Stock

Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. Its products in pipeline include VGX-3100 for the treatment of HPV-related cervical high-grade dysplasia; INO-3107 for HPV-related recurrent respiratory papillomatosis and is under Phase 1/2 trial; INO-3112 for the treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma and is under Phase 2 trial; INO-5401 for the treatment of glioblastoma multiforme and is under Phase 2 trial; INO-4201 for Ebola Virus Disease and is under Phase 1b trial; INO-4800 for COVID-19 and is under Phase 3 trial; and INO-6160 for the treatment of human immunodeficiency virus and is under Phase 1 trial. Its partners and collaborators include Advaccine Biopharmaceuticals Suzhou Co, ApolloBio Corporation, AstraZeneca, The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations, Defense Advanced Research Projects Agency, The U.S. Department of Defense, HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, the University of Pennsylvania, Plumbline Life Sciences, Regeneron Pharmaceuticals, Richter BioLogics, the Walter Reed Army Institute of Research, and The Wistar Institute. The company was incorporated in 1983 and is headquartered in Plymouth Meeting, Pennsylvania. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameINOSectorS&P500
1-Week Return5.11%-1.91%-4.4%
1-Month Return-1.6%-8.22%-10.77%
3-Month Return-17.78%-5.01%-15.29%
6-Month Return-67.54%-10.62%-11.9%
1-Year Return-81.54%-3.17%2.9%
3-Year Return-94.63%1.04%20.61%
5-Year Return-98.68%37.23%84.18%
10-Year Return-98.52%81.65%144.64%

Financials

Dec '20Dec '21Dec '22Dec '23Dec '245YR TREND
Total Revenue7.41M1.77M10.26M832.01K217.76K[{"date":"2020-12-31","value":72.22,"profit":true},{"date":"2021-12-31","value":17.29,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":8.11,"profit":true},{"date":"2024-12-31","value":2.12,"profit":true}]
Cost of Revenue94.25M4.73M5.50M3.50M-[{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":5.02,"profit":true},{"date":"2022-12-31","value":5.83,"profit":true},{"date":"2023-12-31","value":3.72,"profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Gross Profit(86.83M)(2.96M)4.77M(2.67M)217.76K[{"date":"2020-12-31","value":-1821.86,"profit":false},{"date":"2021-12-31","value":-62.02,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-56.05,"profit":false},{"date":"2024-12-31","value":4.57,"profit":true}]
Gross Margin(1171.66%)(166.56%)46.44%(321.09%)100.00%[{"date":"2020-12-31","value":-1171.66,"profit":false},{"date":"2021-12-31","value":-166.56,"profit":false},{"date":"2022-12-31","value":46.44,"profit":true},{"date":"2023-12-31","value":-321.09,"profit":false},{"date":"2024-12-31","value":100,"profit":true}]
Operating Expenses131.49M302.99M277.84M144.77M112.62M[{"date":"2020-12-31","value":43.4,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":91.7,"profit":true},{"date":"2023-12-31","value":47.78,"profit":true},{"date":"2024-12-31","value":37.17,"profit":true}]
Operating Income(124.08M)(301.22M)(267.57M)(143.94M)(112.40M)[{"date":"2020-12-31","value":-12408204400,"profit":false},{"date":"2021-12-31","value":-30121791900,"profit":false},{"date":"2022-12-31","value":-26757352000,"profit":false},{"date":"2023-12-31","value":-14394002800,"profit":false},{"date":"2024-12-31","value":-11239892200,"profit":false}]
Total Non-Operating Income/Expense(44.20M)(579.77K)(6.55M)15.77M(107.14B)[{"date":"2020-12-31","value":-280.24,"profit":false},{"date":"2021-12-31","value":-3.68,"profit":false},{"date":"2022-12-31","value":-41.54,"profit":false},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":-679301.47,"profit":false}]
Pre-Tax Income(162.89M)(303.22M)(277.65M)(135.12M)(107.25B)[{"date":"2020-12-31","value":-16289030400,"profit":false},{"date":"2021-12-31","value":-30322432300,"profit":false},{"date":"2022-12-31","value":-27765285200,"profit":false},{"date":"2023-12-31","value":-13511735200,"profit":false},{"date":"2024-12-31","value":-10725412600000,"profit":false}]
Income Taxes52.20M2.16M10.01M2.00-[{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":4.14,"profit":true},{"date":"2022-12-31","value":19.18,"profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Income After Taxes(215.09M)(305.38M)(287.66M)(135.12M)-[{"date":"2020-12-31","value":-21508644400,"profit":false},{"date":"2021-12-31","value":-30538495800,"profit":false},{"date":"2022-12-31","value":-28766423700,"profit":false},{"date":"2023-12-31","value":-13511735400,"profit":false},{"date":"2024-12-31","value":"-","profit":true}]
Income From Continuous Operations(162.89M)(303.22M)(277.65M)(164.58M)(107.25M)[{"date":"2020-12-31","value":-16289030400,"profit":false},{"date":"2021-12-31","value":-30322432300,"profit":false},{"date":"2022-12-31","value":-27765285200,"profit":false},{"date":"2023-12-31","value":-16457685300,"profit":false},{"date":"2024-12-31","value":-10725412600,"profit":false}]
Income From Discontinued Operations-----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Net Income(215.09M)(305.38M)(287.66M)(135.12M)(107.25M)[{"date":"2020-12-31","value":-21508644400,"profit":false},{"date":"2021-12-31","value":-30538495800,"profit":false},{"date":"2022-12-31","value":-28766423700,"profit":false},{"date":"2023-12-31","value":-13511735200,"profit":false},{"date":"2024-12-31","value":-10725412600,"profit":false}]
EPS (Diluted)(1.10)(1.45)(1.18)(1.54)(3.99)[{"date":"2020-12-31","value":-110,"profit":false},{"date":"2021-12-31","value":-145,"profit":false},{"date":"2022-12-31","value":-118,"profit":false},{"date":"2023-12-31","value":-154,"profit":false},{"date":"2024-12-31","value":-399,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

INO
Cash Ratio 2.66
Current Ratio 2.77

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

INO
ROA (LTM) -49.45%
ROE (LTM) -115.42%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

INO
Debt Ratio Lower is generally better. Negative is bad. 0.39
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.61

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

INO
Trailing PE NM
Forward PE NM
P/S (TTM) 311.57
P/B 0.95
Price/FCF NM
EV/R 128.41
EV/Ebitda NM
PEG NM

FAQs

What is Inovio Pharmaceuticals Inc share price today?

Inovio Pharmaceuticals Inc (INO) share price today is $1.85

Can Indians buy Inovio Pharmaceuticals Inc shares?

Yes, Indians can buy shares of Inovio Pharmaceuticals Inc (INO) on Vested. To buy Inovio Pharmaceuticals Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in INO stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Inovio Pharmaceuticals Inc be purchased?

Yes, you can purchase fractional shares of Inovio Pharmaceuticals Inc (INO) via the Vested app. You can start investing in Inovio Pharmaceuticals Inc (INO) with a minimum investment of $1.

How to invest in Inovio Pharmaceuticals Inc shares from India?

You can invest in shares of Inovio Pharmaceuticals Inc (INO) via Vested in three simple steps:

  • Click on Sign Up or Invest in INO stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Inovio Pharmaceuticals Inc shares
What is Inovio Pharmaceuticals Inc 52-week high and low stock price?

The 52-week high price of Inovio Pharmaceuticals Inc (INO) is $13.44. The 52-week low price of Inovio Pharmaceuticals Inc (INO) is $1.42.

What is Inovio Pharmaceuticals Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Inovio Pharmaceuticals Inc (INO) is 0.95

What is the Market Cap of Inovio Pharmaceuticals Inc?

The market capitalization of Inovio Pharmaceuticals Inc (INO) is $64.55M

What is Inovio Pharmaceuticals Inc’s stock symbol?

The stock symbol (or ticker) of Inovio Pharmaceuticals Inc is INO

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top